In End-Stage Heart Failure, Levosimendan Improves Event Free Survival By 50 Percent

Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented during a late breaking trial session of the Heart Failure Congress 2013. In a second study, the third generation mineralocorticoid receptor antagonist (MRA) BAY 94-8862 showed improved potassium and kidney tolerance in heart failure patients with chronic kidney disease (CKD). Heart Failure 2013 is the main annual meeting of the Heart Failure Association of the European Society of Cardiology and was held 25-28 May in Lisbon, Portugal...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Heart Disease Source Type: news